Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00219609 | Assessment Of Safety Of UK-390,957 | PHASE2 | COMPLETED | 1,058 | — | — | Jan 1, 2005 | Mar 1, 2006 | Nov 7, 2012 | 82 | United States, Australia +12 |
| NCT00219635 | Assessment Of Efficacy and Safety UK-390,957 In Men With Premature Ejaculation | PHASE2 | COMPLETED | 138 | — | — | Jan 1, 2005 | Jul 1, 2005 | Nov 7, 2012 | 22 | United States, Australia +2 |
| NCT00143117 | Assessment of Efficacy and Safety of UK-390,957 in Men With Premature Ejaculation | PHASE2 | COMPLETED | 460 | — | — | Aug 1, 2004 | Jun 1, 2005 | Nov 7, 2012 | 51 | United States |
| NCT00219583 | Assessment Of Efficacy and Safety Of UK-390,957 In Men With Premature Ejaculation | PHASE2 | COMPLETED | 460 | — | — | Aug 1, 2004 | Jun 1, 2005 | Nov 7, 2012 | 49 | Australia, Austria +12 |
| Name | Type | Description |
|---|---|---|
| UK-390,957 | DRUG | - |
Inclusion Criteria: * Subjects will have completed one of the phase 2 trials (A3871022/ A3871027/ A3871029) and will have met the diagnostic criteria for premature ejaculation as defined by DSM-IV Exclusion Criteria: * No drug related serious adverse events